Outcome of the Board Meeting

5 August 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Outcome of the Meeting of the Board of Directors Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company (“Board”) at its meeting held today, i.e., 5 August 2026, has, inter alia, approved the following: 1. The Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30 June 2026 pursuant to Regulation 33 of the SEBI Listing Regulations. In this connection, we enclose herewith the following documents as Annexure 1: a) Unaudited Standalone and Consolidated Financial Results; b) Limited Review Reports from the Statutory Auditors on the above financial results; c) Press Release on the financial results; and d) Investor Presentation. 2. Reorganization at Sapala Organics Private Limited ("Sapala"), a subsidiary of the Company and entering into necessary amendment agreement(s) with the selling shareholders of Sapala. In this connection, we enclose herewith the details of the reorganization as Annexure 2. 3. Convening of the 8th Annual General Meeting (AGM) of the Members of the Company on Thursday, 17 September 2026 and related matters. The aforesaid information is also being made available on the Company's website at www.cohance.com. The Board Meeting commenced at 3.30 pm (IST) and concluded at 5:25 pm (IST). We request you to take the above on record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Annexure - 1(a) COHANLCIEF ESCILEINMCIETSE D (formkenrolwaynsS uvPehna rmaceLuitmiictaelds) RegOdf.f2 :1 A5t riuWmi,n 8gtC,Fh l o8o1r9,- 8A2n1d,hK eurriRl oaa Cdh,a kAanldah,Ee arsit , ChakalaM uMmibdacio,, MaIhnadr4ia0as09,h03 t ra, STATEMOEFN TU NAUDITED STANDALONE ANDR ECSOUNLFSTOOSRL IQDUAAETRNETDDEE3 RD0F IJNUANNEC I2AR0Ls2 .6i n Crores PART· I STANDALONE Fotrh qeu aretnedre d Fotrh yee aern ded SIN.o . PARTICULARS 30J un2e0 26 31M ar2c0h2 6 30J un2e02 5 31M ar2c0h2 6 UnauditedU nauditedU naudited Audited terefr note 5 I 1 Income Revenuoep efrraotmi ons 35.899 567.55 48538. 2,030.50 Othienrc ome 1.216 (0.7)9 13.10 44.73 Totianlc ome 372.05 56766. 496.68 2,075.23 2 Expenses a) Cost ocfo nmsautmeerdi als 15910. 13.643 175.16 69.217 b)C haniginen sv enotffo irniiegssoh oedds and work-in-p(r4o31g3 r)e ss 7.676 (29.17) (38.58) c) Empbleonyeeefxeip tesn se 9.634 9,681 103.43 380.43 d)F inance costs 2.12 5.17 6.80 22.46 e)D eprecainaadtm ioornt iesxapteinosne s 34.32 3.766 31.36 133.58 fOlt heexrp enses 126 49 1247.8 129.96 54.927 Total expenses 369.84 493.81 417.54 1,732.13 3 Probfeiftoe rxec eptiitoen&mta sal (x 1 ·2) 2,21 72.95 79.14 343.10 4 Exceptiitoe(nmrasel n/ oetre 4) 16.51 8.10 29.47 5 Probfeiftot raex (3-4) 2.21 56,44 71.04 313.63 6 Taexx penses aJ Cutrarxe nt 169. 3 1.81 5 73.41 b)C urreneta rtylaeixae·rr s 46,9 4.69 c)D efetrarxe d 0.80 0,80 0.32 6.82 Tottaalex x oneslen tel 0.80 21.88 18.47 84.92 7 Neotr offoirl the oeriod/vear/5-6) 1,41 34.56 52.57 228.71 8 Other compirnechoe(mnleso/is vse) 8.aI tetmhswa itnl olbt er eclatsosp irfooifrlei odts s (i) oGnra eimne asuorfde emfeinbntee ndep fliatn 0.20 2.20 0.11 2.05 Jii) Incomteoi tteatmxhs wa ritel llba ertn eiocntlg a sspirfoifeidt to( 00 5) (0 56) (.003) (0.52) or loss 8.bI tetmhsaw ti ll be trope rcolfalisotss isfo ire d (i) Effecotfgi avi/en (polonohr setsdi)go inn g incsatsrhu ment 7i.8n7 a (5.54) (993.) Flohwed ging (IIlnlc otmarexe lattoi niQt ewmisbl elrt ehcalta tsosp irfooifrei dt (1.98) 1.40 2.50 Totoatlh ceorm prehen5lvef oitrnh cpeoe mrei/oldl/oysesalr 6.04 12.SOl 0.08 (.5910 9 Total compirnechofoemrne 5 tihvee period/year (7+78.)4 5 32.06 52.65 222.81 10 Paide-quupis thyac raep ital 38.26 38.26 38.26 386. 2 FacVea loufte h Seh are i{1.00 i{l.00 �1.00 �1.00 11 Otheeqru ity 4,441.85 12 EarninSgh a(PrEeePr S )v-aFlaoucffee 1 /e-ach) a)Basic 0.04 0.90 1.38 5.98 b) Diluted 0.04 0.90 1.37 5.97 (not annu(anlaointsn euda)l i(sneaodnt)n ualis(eadn)n ualised) COHANCE LIFESCIENCES LIMITED (formerly known as Suven Pharmaceuticals Limited) Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Mldco, Mumbai, Maharashtra, lndta, 400093 PART -II CONSOLIDATED For the quarter ended For the year ended SI. No. PARTICULARS 30 June 2026 31 March 2026 30 June 2025 31 March 2026 Unaudited Unaudited Unaudited Audited (reler 11ote 51 1 Income Revenue from operations 422.26 619.12 549.31 2,268.55 Other Income 12.25 11.841 14.17 34.09 Total income 434.51 617.28 563.48 2,302.64 2 Expenses aJ Cost of materials consumed 158.68 138.96 178.33 705.39 b) Changes in inventories of finished goods and work-in-progress (38.40) 75.49 (30.19) (42,76) c) Employee benefits expense 132.96 128.99 133.32 507.71 d) Finance costs 6 74 9.19 10.18 37.24 e) Depreciation and amortisation expenses 49.54 51.23 45.14 187.33 () Other expenses 167.86 177.00 155.84 671.22 Total expense.s 477.38 580.86 492.62 2,066.13 3 Proflt/(loss) before tax and exceptional items (1·1) (42.87) 36.41 70.86 236.51 4 Exceptional items (refer note 4) 16.51 8.10 29.47 5 ProOt/(lossl before tax and share of associate (3·41 142.871 19.91 61.76 207.04 6 Tax expenses a) Current tax 2.13 17.55 18 18 75.20 b) Current tax • earlier years 0.04 4.69 4.69 cJ Deferred tax 0.15 (10.64) (1,821 (22.97) Total tax expense (net) 2.32 11.60 16.36 56.92 7 Net profitl(loss) after tax before share of associate (5-6) (45.19) 8.31 46.40 150.12 8 Share or profit./ floss) of Associate 9 Net profit/(loss) for the period/year (7·8) (45.19) 8.31 46.40 150.12 10 Net profft/(loss) for the period/year attributable to a) Shareholders or the company (24.12) 19.55 48.88 179.23 b)· Non-controlUnQ interest (21.071 (11.24) 12.48) (29.11) 11 Other comprehensive incomel(loss) - 11.a Items that will not be reclaJsiried to profit or loss (i) Gain /(loss) on remeasurement of defined benefit plan 0.19 2.28 0.11 2.13 (ii) Change in the fair value of equity Instrument classified at FVOCI 94.65 94.65 (If() Income tax relating to items that will not be reclassified to profit (O.OS) (26.60) (0.03) (26.56) or loss 11.b Items that will be reclassified to profit or loss (i) Effective portion of gain I (loss) on hedging instrument in a cash 7.87 (5.54) (9.93) flow hedging (ii) Exchange differences on Translating foreign operations (0.24) 19.88 (0.MJ 36.25 (iii) Income tax relating to items that will be reclassified to profit or (1 98) 1 40 2.50 loss Total other comprehensive income/(loss) for the period/year 5.79 86.07 (0.06) 99.04 12 Total comprehensive lncome/(loss) for the perlodtvear (9+ 11) (39.401 94.38 46.34 249.16 13 Total comprehensive income/(loss) for the period/year attributable to a) Shareholders of the company (18.29) 101. 91 48.82 270.68 b) Non-controlling interest (21.11: (7.53) (2.◄81 (21.52) 14 Paid-up equity share capital 38.26 38.26 38.26 38.26 Face value of the share 't1.00 't1.00 't1.00 ,1.00 15 Other equity 3,873.03 16 Earning Per Share (EPS)-(Face value of 1'1/-each) a) Basic (0.63) 0.51 1.28 4.69 b) Diluted (0.65) 0.50 1.27 4.68 (not annualised) (not annualised) (not annualised) (annualised) COHANCE LIFESCIENCES LIMITED (formerly known as Suven Pharmaceuticals limited) Regd. Off: 215 Atrtum, C Wing, 8th Floor, 819-121, Andheri Kurla Road, Chakala, Andherf East, Chakala Mldco. Mumba1. Maharashtra, Tndf11, ◄00093 Notes I) The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board or Olte<:ton; al its meeting held on S August 2026~ These results have been subjected to limited review by statutory auditors who have expre [Showing first 8,000 characters — download PDF for full document]